These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9566050)

  • 1. Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide.
    Sloderbach A; Hładoń B; Sochacki M; Kinas R; Kuśnierczyk H; Laskowska H
    Pol J Pharmacol; 1997; 49(6):463-9. PubMed ID: 9566050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and bioavailability of stereoisomeric analogues of ifosfamide.
    Sloderbach A; Hładoń B; Laskowska H
    Acta Physiol Hung; 1996; 84(4):459-60. PubMed ID: 9328631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of phenobarbital on stereoselective metabolism of ifosfamide in rats.
    Lu H; Wang JJ; Chan KK; Young D
    Drug Metab Dispos; 1998 May; 26(5):476-82. PubMed ID: 9571229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of (-)-(S)-bromofosfamide after intravenous and oral administration in mice.
    Kobylińska K; Kobylińska M; Sobik B
    Arzneimittelforschung; 2001; 51(7):596-9. PubMed ID: 11505792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enantioselective cytotoxic activity of bromine-substituted analogues of ifosfamide. A microsomal implication.
    Hładoń B; Sloderbach A; Laskowska H
    Pol J Pharmacol; 1997; 49(2-3):127-36. PubMed ID: 9437759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and bioavailability of oral ifosfamide.
    Wagner T; Drings P
    Arzneimittelforschung; 1986 May; 36(5):878-80. PubMed ID: 3730024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
    Kaijser GP; Keizer HJ; Beijnen JH; Bult A; Underberg WJ
    Anticancer Res; 1996; 16(5B):3247-57. PubMed ID: 8920799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of ifosfamide and some metabolites in children.
    Kaijser GP; De Kraker J; Bult A; Underberg WJ; Beijnen JH
    Anticancer Res; 1998; 18(3B):1941-9. PubMed ID: 9677448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis of potential metabolites of (S)-(-)-bromofosfamide.
    Misiura K
    Pharmazie; 2004 Sep; 59(9):668-72. PubMed ID: 15497745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological properties of racemic chlorobromofosfamide.
    Juszkiewicz M; Kleinrok Z; Sawiniec Z
    Arch Immunol Ther Exp (Warsz); 1994; 42(5-6):405-13. PubMed ID: 8572900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rodent pharmacokinetics and receptor occupancy of the GABAA receptor subtype selective benzodiazepine site ligand L-838417.
    Scott-Stevens P; Atack JR; Sohal B; Worboys P
    Biopharm Drug Dispos; 2005 Jan; 26(1):13-20. PubMed ID: 15578749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial and pharmacokinetic analysis of ifosfamide in cats with sarcomas.
    Rassnick KM; Moore AS; Northrup NC; Kristal O; Beaulieu BB; Lewis LD; Page RL
    Am J Vet Res; 2006 Mar; 67(3):510-6. PubMed ID: 16506919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
    Kerbusch T; Mathôt RA; Keizer HJ; Kaijser GP; Schellens JH; Beijnen JH
    Drug Metab Dispos; 2001 Jul; 29(7):967-75. PubMed ID: 11408362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stereoselective pharmacokinetics of flobufen in rats.
    Trejtnar F; Wsol V; Szotakova B; Skalova L; Pavek P; Kuchar M
    Chirality; 1999; 11(10):781-6. PubMed ID: 10561708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of mesna on urotoxic effects of selected bromosubstituted analogs of ifosfamide.
    Kuśnierczyk H; Konarski L; Kowalski P; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1997; 45(1):79-85. PubMed ID: 9090445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450.
    Chen CS; Jounaidi Y; Waxman DJ
    Drug Metab Dispos; 2005 Sep; 33(9):1261-7. PubMed ID: 15919850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue therapy.
    Aeschlimann C; Küpfer A; Schefer H; Cerny T
    Drug Metab Dispos; 1998 Sep; 26(9):883-90. PubMed ID: 9733667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Route-dependent stereoselective pharmacokinetics of tramadol and its active O-demethylated metabolite in rats.
    Parasrampuria R; Vuppugalla R; Elliott K; Mehvar R
    Chirality; 2007 Mar; 19(3):190-6. PubMed ID: 17192836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efforts to establish an animal model of Fanconi syndrome after ifosfamide administration to rats.
    Appenroth D; Werner T; Lupp A; Patzer L; Misselwitz J; Fleck C
    J Appl Toxicol; 2007; 27(4):327-36. PubMed ID: 17265418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.